JW Pharmaceutical’s ‘Emicizumab’ designated as orphan drug treating hemophilia A
‘Emicizumab,’ a hemophilia A treatment which has been widely known to become a global new drug, has also raised attention of patients as being designated as an orphan drug even in Korea.
JW Pharmaceutical announced on the 21st that ‘Emicizumab,’ a hemophilia A treatment which secured an exclusiv...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
